Discovery and characterization of AZD9272 and AZD6538—Two novel mGluR5 negative allosteric modulators selected for clinical development
Graphical abstract
Section snippets
Acknowledgments
The authors are grateful to Pam Jacobson and the core tissue culture group at NPS Salt Lake City for their contribution to developing the cell lines, to Julie Grabell and Josee Normand (NPS Toronto) for their technical assistance in developing and implementing binding studies and IP assay, to Brad VanWagenen (NPS SLC) for his contribution to chemistry and to the late Allan Johnson (AstraZeneca) who designed and performed the autoradiographic studies.
We also want to thank Edwin Johnson
References and notes (38)
- et al.
Neuropharmacology
(2000) - et al.
Pharmacol. Biochem. Behav.
(2002) - et al.
Trends Neurosci.
(2004) - et al.
Neuropharmacology
(2001) - et al.
Neuropharmacology
(2001) - et al.
Eur. J. Pharmacol.
(2005) - et al.
Neuropharmacology
(1999) - et al.
Bioorg. Med. Chem. Lett.
(2004) - et al.
Bioorg. Med. Chem. Lett.
(2004) - et al.
Eur. J. Pharmacol.
(2003)
Brain Res. Dev. Brain Res.
(1999)
Neuroimage
(2012)
Eur. J. Pharm. Sci.
(2009)
J. Pharmacol
Toxicol. Methods
(2006)
Curr. Drug Targets CNS Neurol. Disord.
(2002)
Nat. Neurosci.
(2001)
Mov. Disord.
(2011)
CNS Neurol. Disord. Drug Targets
(2009)
Br. J. Pharmacol.
(2001)
Cited by (0)
Copyright © 2012 Elsevier Ltd. All rights reserved.